cisplatin + gemcitabine + tirapazamine

A combination chemotherapy regimen consisting of cisplatin, gemcitabine, and tirapazamine. This triplet therapy combines two conventional chemotherapy agents (cisplatin and gemcitabine) with tirapazamine, a hypoxic cytotoxin that specifically targets cancer cells in low-oxygen environments. ## Mechanism of Action This combination leverages multiple mechanisms to attack cancer cells: 1. Cisplatin works by forming DNA adducts that interfere with DNA replication and transcription, leading to cell death. 2. Gemcitabine is a nucleoside analog that inhibits DNA synthesis and induces apoptosis in cancer cells. 3. Tirapazamine is a benzotriazine compound that becomes activated in hypoxic environments, common in solid tumors. It creates DNA damage specifically in oxygen-deprived cancer cells that are often resistant to conventional treatments[1][3]. The combination shows synergistic effects, particularly when tirapazamine is administered before cisplatin, as tirapazamine appears to inhibit the repair of cisplatin-induced DNA damage[3]. This schedule dependency has been observed in multiple studies, with most indicating enhanced efficacy when tirapazamine precedes cisplatin administration[3]. ## Clinical Evidence A Phase II trial evaluated this triplet combination in 45 patients with advanced or metastatic NSCLC (stage IIIb: 20 patients, stage IV: 25 patients). The regimen consisted of: - Tirapazamine 330 mg/m² (day 1) - Cisplatin 75 mg/m² (day 1) - Gemcitabine 1250 mg/m² (days 1 and 8) This treatment was administered every 3 weeks[1]. The results showed: - Response rate: 40% - Median progression-free survival: 6.7 months (range: 4.8-8.1 months) - Median overall survival: 8.1 months (range: 7.5-12.5 months) - One-year survival rate: 35%[1] ## Toxicity Profile The triplet combination demonstrated manageable toxicity: **Hematological toxicities:** - Neutropenia (CTC grade 3 and 4): 20% - Thrombocytopenia (CTC grade 3 and 4): 16% **Non-hematological toxicities:** - Nausea and vomiting (CTC grade 3): 5%[1] The most common side effect specifically attributed to tirapazamine was muscular cramping, which was dose-limiting in some cases[3]. Unlike other drugs commonly combined with cisplatin (such as taxols, 5-FU, or gemcitabine alone), tirapazamine did not significantly potentiate cisplatin's side effects, making this an advantageous combination[3]. ## Development Status This combination has been studied in Phase II clinical trials for advanced NSCLC with promising results. The search results indicate that further Phase III trials were planned or in progress at the time of publication[1][4]. However, the current approval status is not clearly specified in the provided information. While the combination of gemcitabine and cisplatin alone has become a standard treatment option for advanced NSCLC with response rates of approximately 40% in Phase II trials and median survival of about one year[4], the addition of tirapazamine to this regimen was being investigated to potentially improve outcomes for patients with hypoxic tumors.